Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.
PSMA-PET
androgen-receptor signaling inhibitors
apalutamide
conventional imaging
darolutamide
enzalutamide
nmCRPC
nonmetastatic castration-resistant prostate cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
31 Mar 2022
31 Mar 2022
Historique:
received:
13
02
2022
revised:
28
03
2022
accepted:
29
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
Nonmetastatic castration-resistant prostate cancer (nmCRPC) represents a condition in which patients with prostate cancer show biochemical progression during treatment with androgen-deprivation therapy (ADT) without signs of radiographic progression according to conventional imaging. The SPARTAN, ARAMIS and PROSPER trials showed that apalutamide, darolutamide and enzalutamide, respectively, prolong metastasis-free survival (MFS) and overall survival (OS) of nmCRPC patients with a short PSA doubling time, and these antiandrogens have been recently introduced in clinical practice as a new standard of care. No direct comparison of these three agents has been conducted to support treatment choice. In addition, a significant proportion of nmCRPC on conventional imaging is classified as metastatic with new imaging modalities such as the prostate-specific membrane antigen positron emission tomography (PSMA-PET). Some experts posit that these "new metastatic" patients should be treated as mCRPC, resizing the impact of nmCRPC trials, whereas other authors suggest that they should be treated as nmCRPC patients, based on the design of pivotal trials. This review discusses the most convincing evidence regarding the use of novel antiandrogens in patients with nmCRPC and the implications of novel imaging techniques for treatment selection.
Identifiants
pubmed: 35406564
pii: cancers14071792
doi: 10.3390/cancers14071792
pmc: PMC8997634
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Cancer Treat Rev. 2017 Jun;57:16-27
pubmed: 28527407
Urology. 2010 Nov;76(5):1189-93
pubmed: 20303155
Cancer Res. 2012 Mar 15;72(6):1494-503
pubmed: 22266222
J Clin Oncol. 2019 May 1;37(13):1120-1129
pubmed: 30865549
Eur Urol. 2015 Jun;67(6):1009-1016
pubmed: 25308970
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
Eur Urol Oncol. 2018 Dec;1(6):467-475
pubmed: 31158090
N Engl J Med. 2013 Jan 10;368(2):138-48
pubmed: 23228172
J Clin Oncol. 2016 Jun 20;34(18):2098-106
pubmed: 26811535
Lancet. 2020 Apr 11;395(10231):1208-1216
pubmed: 32209449
Lancet. 2000 Apr 29;355(9214):1491-8
pubmed: 10801170
JAMA Oncol. 2019 Apr 01;5(4):471-478
pubmed: 30589920
J Clin Oncol. 2013 May 10;31(14):1748-57
pubmed: 23569316
Sci Rep. 2015 Jul 03;5:12007
pubmed: 26137992
Lancet Oncol. 2018 Jan;19(1):76-86
pubmed: 29248236
Crit Rev Oncol Hematol. 2017 Oct;118:42-53
pubmed: 28917268
Eur Urol. 2016 Dec;70(6):963-970
pubmed: 27160947
N Engl J Med. 2018 Jun 28;378(26):2465-2474
pubmed: 29949494
Lancet. 2012 Jan 7;379(9810):39-46
pubmed: 22093187
J Clin Oncol. 2018 Aug 20;36(24):2492-2503
pubmed: 29985747
Cancers (Basel). 2019 Sep 12;11(9):
pubmed: 31547436
Eur Urol. 2021 Jan;79(1):150-158
pubmed: 32907777
Urology. 2014 Mar;83(3):664-9
pubmed: 24411213
Eur Urol. 2019 Jun;75(6):967-987
pubmed: 30342843
Lancet Oncol. 2015 Jun;16(6):e279-92
pubmed: 26065613
Cancer Res. 2016 Feb 15;76(4):912-26
pubmed: 26645563
J Clin Oncol. 2019 Feb 20;37(6):490-503
pubmed: 30625039
BJU Int. 2006 Jun;97(6):1184-9
pubmed: 16686709
Lancet. 2022 Jan 29;399(10323):447-460
pubmed: 34953525
Urology. 2003 Dec 29;62 Suppl 1:87-94
pubmed: 14747046
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
N Engl J Med. 2018 Jun 28;378(26):2531-2532
pubmed: 29949488
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
Prostate. 2018 May;78(7):498-505
pubmed: 29473179
N Engl J Med. 2020 Jun 4;382(23):2197-2206
pubmed: 32469184
Lancet Oncol. 2016 Jun;17(6):727-737
pubmed: 27155740
Eur Urol Focus. 2021 Aug 31;:
pubmed: 34479838
N Engl J Med. 2020 Sep 10;383(11):1040-1049
pubmed: 32905676
Nat Rev Clin Oncol. 2017 May;14(5):269-283
pubmed: 27874061
N Engl J Med. 2018 Apr 12;378(15):1408-1418
pubmed: 29420164
Cancers (Basel). 2021 Sep 08;13(18):
pubmed: 34572748
Cancers (Basel). 2019 Sep 13;11(9):
pubmed: 31540293
Mol Cell. 2007 Dec 14;28(5):739-45
pubmed: 18082599
JAMA Oncol. 2016 Nov 01;2(11):1441-1449
pubmed: 27262168
J Urol. 2018 Nov;200(5):956-966
pubmed: 29730201
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268
pubmed: 28497198
JAMA Oncol. 2021 Jul 1;7(7):1005-1014
pubmed: 34081076
J Clin Oncol. 2017 Sep 20;35(27):3097-3104
pubmed: 28796587
Eur Urol. 2020 Jun;77(6):763-766
pubmed: 32143923
Nat Genet. 2018 May;50(5):645-651
pubmed: 29610475
J Clin Oncol. 2019 May 10;37(14):1159-1168
pubmed: 30860948
J Clin Oncol. 2008 Mar 1;26(7):1148-59
pubmed: 18309951
Lancet Oncol. 2014 Aug;15(9):975-85
pubmed: 24974051
J Clin Oncol. 2013 Oct 20;31(30):3800-6
pubmed: 24043751
Eur Urol. 2021 May;79(5):565-567
pubmed: 32847699
J Natl Cancer Inst. 2021 May 4;113(5):553-561
pubmed: 32857839
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Anticancer Drugs. 2016 Nov;27(10):917-43
pubmed: 27400375
JAMA Oncol. 2015 Aug;1(5):582-91
pubmed: 26181238
Clin Cancer Res. 2019 Dec 15;25(24):7448-7454
pubmed: 31511295
Cancer. 2008 Jun;112(11):2393-400
pubmed: 18383517
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
N Engl J Med. 2019 Mar 28;380(13):1235-1246
pubmed: 30763142
Eur Urol. 2011 Jun;59(6):893-9
pubmed: 21388736
J Urol. 2018 Aug;200(2):344-352
pubmed: 29630978
Eur J Cancer. 2021 Dec;159:237-246
pubmed: 34784577
J Urol. 2008 Sep;180(3):921-7
pubmed: 18635218
Eur Urol. 2015 Aug;68(2):186-93
pubmed: 25454609
J Clin Oncol. 2017 Jul 1;35(19):2149-2156
pubmed: 28384066
Eur J Cancer. 2021 Sep;154:138-146
pubmed: 34273811